OA 09.06 A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
Jin‐Ji Yang(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences), C.Z. Zhou(Tongji University), Melanie M. Frigault(Vifor Pharma (United States)), Coumaran Égile(AstraZeneca (United Kingdom)), Shethah Morgan(AstraZeneca (United Kingdom)), G. Chen(Harbin Medical University), Xuan Liu(307th Hospital of Chinese People’s Liberation Army), Jian Fang(Peking University), Ling Yang, Jianan Huang(Soochow University), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Yongqian Shu(Jiangsu Province Hospital), A.A. Handzel, J. Chang(Fudan University Shanghai Cancer Center), W. Li(Jilin University), Ning Yang(First Affiliated Hospital of Hebei Medical University), G. Ahmed
Cited by 18
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k